Bio tech company updates — 8/24/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biotech giant Hanmi Pharmaceutical has secured a major international licensing deal with Genentech for its muscle-sparing obesity drug candidate, valued at up to $2.3 billion. Simultaneously, the Financial Services Supervisory (FSS) announced it will host briefings next month to explain new disclosure rules specifically for pharmaceutical and biotech companies.
Key Findings
- Major Licensing Agreement: Hanmi Pharmaceutical has licensed its muscle-sparing obesity drug candidate, HM17321, to Roche's Genentech in a transaction worth up to $2.3 billion.
- Regulatory Update: South Korea's FSS is scheduled to hold four briefings next month to clarify new pharmaceutical and biotech disclosure rules for listed firms and IPO candidates.
Details
The most significant development in the Korean biotech sector over the past 24 hours is the commercialization milestone achieved by Hanmi Pharmaceutical. The company has entered into a licensing agreement with Genentech, a subsidiary of Roche, for its obesity drug candidate HM17321. This asset is specifically noted for its "muscle-sparing" properties, addressing a common side effect in weight-loss therapies. The total value of the deal is reported to be up to $2.3 billion.
In parallel with corporate developments, the regulatory landscape is shifting. The Financial Services Supervisory (FSS) of South Korea has announced plans to conduct four educational briefings in September. These sessions are designed to help listed pharmaceutical and biotech companies, as well as those preparing for an IPO, understand and comply with newly implemented disclosure regulations.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
